Related Experiment Videos
[Clinical course following mitral valvuloplasty]
T M Suter1, O M Hess, F R Eberli
1Departement für Innere Medizin, Kardiologie, Universitätsspital Zürich.
Schweizerische Medizinische Wochenschrift
|March 6, 1993
Summary
Percutaneous transvenous mitral valvuloplasty effectively treats severe mitral stenosis, improving valve area and patient function. This minimally invasive procedure offers a beneficial and stable clinical outcome for most patients with a low complication rate.
Area of Science:
- Cardiology
- Interventional Cardiology
- Cardiac Surgery
Context:
- Severe mitral stenosis significantly impairs cardiac function and quality of life.
- Non-calcified or minimally calcified mitral valves are candidates for valvuloplasty.
- Percutaneous transvenous mitral valvuloplasty (PTMV) offers a less invasive alternative to surgical intervention.
Purpose:
- To evaluate the efficacy and safety of the double-balloon technique for percutaneous transvenous mitral valvuloplasty (PTMV) in patients with severe mitral stenosis.
- To assess the procedural success rate, hemodynamic changes, functional improvement, and long-term outcomes of PTMV.
- To analyze complications associated with the PTMV procedure.
Summary:
- The study involved 25 patients with severe mitral stenosis undergoing PTMV using a double-balloon technique.
- Successful valvuloplasty was achieved in 88% of patients, significantly increasing mitral valve area and improving New York Heart Association functional classification.
- Follow-up at 24 months showed sustained benefits, with a slight decrease in mitral valve area but stable functional capacity. Complications occurred in 8% of patients.
Impact:
- PTMV is a highly effective treatment for severe, non-calcified mitral stenosis, offering significant hemodynamic and functional improvements.
- The procedure demonstrates a favorable safety profile with a low rate of serious complications.
- Sustained clinical benefits and stable functional capacity observed during long-term follow-up support PTMV as a valuable therapeutic option.